News stories about Pieris Pharmaceuticals (NASDAQ:PIRS) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.7059696554627 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 5.51 on Friday. The company has a 50 day moving average of $5.24 and a 200 day moving average of $3.87. Pieris Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $6.20. The stock’s market capitalization is $244.14 million.

Several equities analysts recently commented on the stock. BidaskClub lowered shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. Rodman & Renshaw assumed coverage on shares of Pieris Pharmaceuticals in a research report on Tuesday, May 30th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, TheStreet lowered shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research report on Monday, June 12th. Five equities research analysts have rated the stock with a buy rating, Pieris Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $8.25.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Pieris Pharmaceuticals (PIRS) Share Price” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/01/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-pieris-pharmaceuticals-pirs-share-price.html.

In other Pieris Pharmaceuticals news, Director James A. Geraghty purchased 10,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The stock was purchased at an average cost of $4.82 per share, with a total value of $48,200.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $48,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Allan Reine purchased 65,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The stock was acquired at an average cost of $4.82 per share, with a total value of $313,300.00. Following the completion of the acquisition, the insider now directly owns 45,000 shares of the company’s stock, valued at $216,900. The disclosure for this purchase can be found here. Corporate insiders own 4.05% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Insider Buying and Selling by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.